Echo Therapeutics Announces Issuance of New Patent for Symphony(TM) Transdermal Continuous Glucose Monitoring System

    FRANKLIN, Mass., Oct. 16 /CNW/ -- Echo Therapeutics (OTC Bulletin Board:  
ECTE) announced the issuance of U.S. Patent 7,432,069 covering compositions
and methods for the preparation of a polyethylene glycol (PEG)-based hydrogel
as a key component of Echo's Symphony(TM) Transdermal Continuous Glucose
Monitoring (tCGM) System.

    "Our proprietary PEG hydrogel, specifically designed to enable
transdermal biosensing, is characterized by excellent stability, sensitivity,
integrity and biocompatibility, making our Symphony tCGM System a desirable
system for non-invasive continuous glucose monitoring," stated Patrick Mooney,
M.D., Echo's Chairman and CEO.  "This patent is critical to our intellectual
property strategy for protecting our leading position in non-invasive, tCGM
markets worldwide."

    Echo's Symphony(TM) tCGM System is in late-stage development for both the
diabetes home use and hospital critical care settings. Symphony incorporates
Echo's new Prelude(TM) SkinPrep System with patented, leading-edge skin
permeation control technologies.

    About Echo Therapeutics
    Echo Therapeutics is focused on late-stage development of transdermal
diagnostic devices and specialty pharmaceuticals. Echo is developing a
non-invasive (needle-free), transdermal continuous glucose monitoring system
together with novel transdermal reformulations of existing FDA-approved

    Forward Looking Statements
    Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current expectations,
but are subject to a number of risks and uncertainties. The factors that could
cause actual future results to differ materially from current expectations
include, but are not limited to, risks related to regulatory approvals and the
success of Echo's ongoing clinical studies regarding the efficacy of its
Symphony tCGM System, the failure of future development and preliminary
marketing efforts related to Echo's tCGM System, risks and uncertainties
relating to Echo's ability to develop, market and sell diagnostic products
based on its skin permeation platform technologies, including the Prelude
SkinPrep System, the availability of substantial additional equity or debt
capital to support its research, development and product commercialization
activities, and the success of its research, development, and regulatory
approval, marketing and distribution plans and strategies, including those
plans and strategies related to its Symphony tCGM System.  These and other
factors are identified and described in more detail in Echo's filings with the
Securities and Exchange Commission, including, without limitation, its annual
report on Form 10-KSB for the year ended December 31, 2007, its quarterly
reports on Form 10-Q, and its current reports on Form 8-K. The foregoing list
of factors is not exhaustive. Echo Therapeutics, Inc. undertakes no obligation
to publicly update or revise any forward-looking statements.


    Investor Relations Contacts:

    Patrick T. Mooney, M.D.
    Chairman and CEO
    Echo Therapeutics

    Melanie Friedman
    Stern Investor Relations


For further information:

For further information: Patrick T. Mooney, M.D., Chairman and CEO of
Echo Therapeutics, +1-508-530-0329; or Melanie Friedman of Stern Investor
Relations for Echo Therapeutics, +1-212-362-1200

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890